This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
by Kinjel Shah
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.
AMGNPositive Net Change ABBVPositive Net Change CEREPositive Net Change GMABPositive Net Change
biotechs pharmaceuticals
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
by Zacks Equity Research
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.
SNYNegative Net Change QURENegative Net Change IDYAPositive Net Change KYMRPositive Net Change HLVXPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian
by Zacks Equity Research
Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian are included in this Analyst Blog.
AZNNegative Net Change NVONegative Net Change ABBVPositive Net Change UGNegative Net Change AIRTNegative Net Change
pharmaceuticals
Top Medical Stocks to Buy for Growth & Performance
by Shaun Pruitt
The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
HAEPositive Net Change HALONegative Net Change NBIXPositive Net Change
cancer earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals
Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG).
AZNNegative Net Change NVONegative Net Change MDTPositive Net Change APHPositive Net Change LRCXPositive Net Change ABBVPositive Net Change
pharmaceuticals
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
by Zacks Equity Research
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
CORTPositive Net Change TRDANegative Net Change ZVRANegative Net Change
biotechnology biotechs medical pharmaceuticals
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates make the stock attractive
GSKPositive Net Change PFEPositive Net Change HLNPositive Net Change
pharmaceuticals
uniQure (QURE) Soars on New Huntington's Disease Study Data
by Zacks Equity Research
uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.
CGENNo Net Change QURENegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
by Zacks Equity Research
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
CGENNo Net Change IDYAPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
by Zacks Equity Research
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
NVONegative Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
by Zacks Equity Research
Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.
MRKNegative Net Change LLYNegative Net Change ABBVPositive Net Change MORFNegative Net Change
pharmaceuticals
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
by Zacks Equity Research
Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
SNYNegative Net Change ADMAPositive Net Change KYMRPositive Net Change TRDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.
ACETPositive Net Change CGENNo Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
by Zacks Equity Research
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
RHHBYPositive Net Change PFEPositive Net Change SRPTNegative Net Change RGNXNegative Net Change SLDBPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
by Zacks Equity Research
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
CGENNo Net Change IMVTPositive Net Change ALXONegative Net Change DNTHPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
by Ekta Bagri
While Gilead (GILD) has been reeling under pressure year to date due to pipeline setbacks, holding on to this biotech giant will be prudent at current levels.
GSKPositive Net Change GILDPositive Net Change MRUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.
AZNNegative Net Change RAPTPositive Net Change ALGSNo Net Change ACRVPositive Net Change
pharmaceuticals
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
by Kinjel Shah
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
SNYNegative Net Change AZNNegative Net Change RHHBYPositive Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
by Zacks Equity Research
The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.
REGNPositive Net Change RHHBYPositive Net Change CGENNo Net Change ALXONegative Net Change
biotechnology medical pharmaceuticals
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
by Zacks Equity Research
Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.
CGENNo Net Change APLSPositive Net Change ALXONegative Net Change ALGSNo Net Change
biotechnology biotechs medical pharmaceuticals
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
RHHBYPositive Net Change MRKNegative Net Change CGENNo Net Change ALXONegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
GSKPositive Net Change MRNAPositive Net Change RCKTNegative Net Change CVACPositive Net Change RNACPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
by Sundeep Ganoria
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
NVONegative Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
by Zacks Equity Research
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
NERVNo Net Change ARGXPositive Net Change ALXONegative Net Change RNACPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
by Zacks Equity Research
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
CGENNo Net Change ANVSPositive Net Change ALXONegative Net Change ALGSNo Net Change
biotechnology biotechs medical pharmaceuticals